Neuron-specific enolase, or NSE, is an enzyme found mainly in neurons and neuroendocrine cells. A serum NSE blood test can be used as an additional tumor marker for small cell lung cancer (SCLC), neuroblastoma, and some other neuroendocrine tumors. It is most useful for following a tumor that was already shown to produce NSE, because levels often fall with successful treatment and may rise again with progression or recurrence. NSE is not specific enough to diagnose cancer by itself. Hemolysis during the blood draw can falsely increase the result, and neurologic injury, severe illness, and some non-small cell cancers can also raise NSE. Reference limits vary by method; one current laboratory uses a serum value of 15 ng/mL or less. In SCLC, higher pretreatment NSE often correlates with more extensive disease and worse prognosis at the population level, but it cannot replace tissue diagnosis, imaging, staging, or clinical assessment. A result is most meaningful when interpreted as part of a trend using the same laboratory method.
- What it measures: NSE measures the gamma-enolase enzyme associated with neural and neuroendocrine tissues, usually reported in ng/mL.
- Typical reference limit: One current assay uses ≤15 ng/mL; laboratories and methods differ, so use the range on the report.
- High levels: SCLC, neuroblastoma, and some neuroendocrine tumors can raise NSE, but hemolysis and neurologic tissue injury can also cause elevations.
- Best use: NSE is strongest as a follow-up marker when a known tumor produced an elevated level before treatment.
- Important sample issue: Red blood cell or platelet contamination and hemolysis can produce a false high result and may require repeat testing.
Table of Contents
- What NSE Is
- Why the NSE Test Is Ordered
- NSE Reference Range and High Levels
- NSE and Small Cell Lung Cancer
- NSE in Other Neuroendocrine Tumors
- Testing, Preparation, and Interference
- Monitoring and Result Meaning
What NSE Is
Enolase is an enzyme involved in glycolysis, the pathway cells use to produce energy from glucose. Several enolase forms exist. The gamma subunit, commonly called neuron-specific enolase, is concentrated in neurons and cells with neuroendocrine features.
Many neuroendocrine cancers retain this protein and can release NSE into the bloodstream. Small cell lung cancer is the classic example because SCLC has strong neuroendocrine differentiation. NSE can also be produced by neuroblastoma, pancreatic neuroendocrine tumors, gastrointestinal neuroendocrine tumors, pheochromocytoma, medullary thyroid carcinoma, and other tumors to varying degrees.
Despite its name, NSE is not found only in neurons. Red blood cells and platelets contain enolase-related activity that can interfere with serum measurement. This practical detail is important because a hemolyzed specimen may appear abnormally high even when the patient’s true circulating NSE is not elevated.
NSE is therefore a nonspecific neuroendocrine-associated marker, not a universal cancer test. It can add information in the right clinical setting but should not be used alone to screen healthy people or classify an unknown tumor.
Why the NSE Test Is Ordered
Clinicians usually order NSE for one of three reasons: to support evaluation when a neuroendocrine malignancy is suspected, to establish a baseline before treatment, or to monitor a known NSE-secreting tumor.
In a patient with a lung mass and features suggestive of SCLC, an elevated NSE can support the clinical picture, but biopsy is still required for diagnosis. In a patient with metastatic cancer of uncertain origin, NSE may be one piece of evidence suggesting neuroendocrine differentiation, again requiring pathology and imaging for confirmation.
NSE can also be useful after a diagnosis has been established. If the level is high before treatment and then falls, the marker may reflect treatment response. If it later rises in a patient who had become NSE-negative or reached a low stable baseline, recurrence or progression becomes one possible explanation.
For well-differentiated gastroenteropancreatic neuroendocrine tumors, NSE is only one of several possible markers. The chromogranin A blood test has historically been used more broadly, although it also has important sensitivity and specificity limitations. Functioning tumors may be better assessed with the specific hormone or metabolite they produce, such as the 5-HIAA test for serotonin-producing neuroendocrine tumors.
NSE is not recommended as a stand-alone population screening test for SCLC. Even though research continues on ways to improve its screening performance, current clinical diagnosis of lung cancer depends on imaging and tissue confirmation rather than a blood marker alone.
NSE Reference Range and High Levels
NSE is usually reported in ng/mL. Reference limits depend on the assay. One current U.S. laboratory uses ≤15 ng/mL as its reference value. Older studies and other laboratories have used cutoffs around 12–16 ng/mL or other thresholds.
| Result pattern | General meaning | Key caution |
|---|---|---|
| Within laboratory range | No measurable NSE elevation | Does not exclude SCLC or another neuroendocrine tumor |
| Mild elevation | May reflect tumor, sample hemolysis, neurologic injury, or another cause | Check specimen quality and clinical context |
| Marked elevation | Can occur with high-burden neuroendocrine malignancy | Still not diagnostic without imaging and pathology |
| Rising serial value | May suggest progression in a known NSE-secreting tumor | Confirm with repeat testing and disease assessment |
A high NSE may be seen with SCLC, neuroblastoma, poorly differentiated neuroendocrine carcinoma, and some other malignancies. It can also rise after brain injury, cardiac arrest, stroke, seizures, or other conditions that injure neurons. NSE is sometimes used in neurologic prognostication after cardiac arrest, which is a separate clinical application from tumor-marker testing.
Hemolysis is a particularly important non-cancer cause of an apparent elevation. If the report notes a hemolyzed specimen or if an unexpected result does not fit the clinical picture, repeating the test with careful collection can be more useful than immediately assuming tumor progression.
NSE and Small Cell Lung Cancer
Small cell lung cancer is a high-grade neuroendocrine carcinoma that usually grows rapidly and has a strong tendency to spread early. Because SCLC cells frequently express neuroendocrine proteins, serum NSE is elevated in a substantial proportion of patients, especially with extensive disease.
NSE can provide three types of information in SCLC:
- Diagnostic support: An elevated level can support SCLC in the appropriate setting, but cannot distinguish SCLC reliably enough to replace biopsy.
- Disease burden: Higher values are more common with extensive disease and multiple metastatic sites.
- Prognosis and monitoring: Elevated pretreatment NSE has been associated with shorter overall and progression-free survival in pooled studies, and serial changes can parallel response.
A meta-analysis of nearly 3,000 SCLC patients found elevated NSE associated with worse overall and progression-free survival. That association applies to groups of patients and should not be used to predict an individual person’s survival from one lab value.
When treatment works, serum NSE can fall relatively quickly. Current laboratory guidance notes an approximate serum half-life of about 24 hours. Persistent elevation after therapy can suggest residual tumor when other explanations have been excluded, while a rising level after prior normalization can raise concern for recurrence.
The key word is suggest. SCLC response assessment still relies on symptoms, imaging, and oncology evaluation. Infection, hemolysis, organ injury, or another cause can move NSE independently of the cancer.
NSE in Other Neuroendocrine Tumors
Neuroendocrine neoplasms are a diverse group. They range from slow-growing, well-differentiated tumors to highly aggressive neuroendocrine carcinomas. This heterogeneity limits the usefulness of any single circulating marker.
In well-differentiated gastroenteropancreatic neuroendocrine tumors, NSE has lower sensitivity than an ideal screening marker. Some studies suggest it is more often elevated in poorly differentiated or higher-grade disease. The level may therefore carry different meaning depending on tumor grade and biology.
In pancreatic neuroendocrine tumors, clinicians may use specific secreted hormones when the tumor is functioning. A nonfunctioning pancreatic neuroendocrine tumor may not produce a syndrome-specific hormone, so general markers may be considered. A pancreatic polypeptide test is another traditional marker with significant limitations and is not interchangeable with NSE.
NSE can also be elevated in neuroblastoma, particularly in advanced or metastatic disease. In pediatric oncology it may contribute to risk assessment or monitoring alongside imaging, pathology, catecholamine metabolites, and other disease-specific studies.
Because neuroendocrine tumors can secrete many different substances, the best marker is often the one that was clearly abnormal in that individual patient at baseline and tracks with known disease activity.
The relationship between NSE and tumor grade is another reason the marker has to be interpreted by disease type. Poorly differentiated neuroendocrine carcinomas often have rapid cell turnover and may release more cytoplasmic NSE than slower-growing well-differentiated tumors. In contrast, a small, indolent, well-differentiated NET may have a normal NSE even when imaging clearly shows disease. A “negative” NSE therefore cannot be used to downgrade a tumor that pathology has already shown to be neuroendocrine.
For small cell lung cancer, NSE is best viewed as a supporting and longitudinal marker, not a screening test for people with smoking history or respiratory symptoms. A chest CT and tissue diagnosis answer questions that NSE cannot: where a lesion is located, whether it is actually cancer, and whether the histology is small cell rather than another lung cancer. The marker becomes more informative after the diagnosis is known and a pretreatment baseline is available.
NSE also overlaps with nonmalignant neurologic medicine. Neurons release NSE after significant brain injury, so concentrations may rise after cardiac arrest, stroke, traumatic brain injury, or prolonged seizures. These situations can be clinically obvious, but they matter when an oncology patient develops an acute neurologic event. A sudden NSE rise after a seizure or resuscitation should not automatically be interpreted as cancer progression.
Another source of confusion is that “neuroendocrine marker” does not mean every neuroendocrine tumor should make NSE. Different tumors express and secrete different proteins. Chromogranin A, peptide hormones, 5-HIAA, or other disease-specific markers may be more informative depending on tumor site and functional status. The best monitoring strategy is individualized around the markers that were abnormal when the patient’s disease was active.
Testing, Preparation, and Interference
The NSE test uses a standard blood draw, but specimen handling requires care. Serum is separated from blood cells, and laboratories may specifically instruct collectors to avoid pneumatic tube transport before centrifugation because mechanical handling can contribute to hemolysis.
Fasting is usually not required for NSE itself. If other tests are drawn at the same visit, follow the preparation instructions for those tests. Prescription medicines should not be stopped unless the treating clinician specifically directs it.
Important sources of misleading results include:
- Hemolysis during collection or transport
- Delayed separation of serum from blood cells
- Platelet contamination
- Rare heterophile antibody interference in immunoassays
- Switching between laboratories that use different methods or reference limits
For serial cancer monitoring, using the same assay when possible improves comparability. A small numerical change after switching laboratories may be methodological rather than biological.
If the result seems implausible—such as a sudden large rise in an otherwise stable patient—the clinician may repeat the test, review the hemolysis index, and compare it with imaging and other markers before changing treatment.
NSE has no universal “tumor-positive” cutoff above the laboratory reference limit. A concentration modestly above normal can come from preanalytic interference or noncancer tissue injury, while very high concentrations are more common in advanced high-grade neuroendocrine disease. The probability of malignancy therefore depends on the patient’s baseline risk and the rest of the diagnostic evidence, not just how many ng/mL the result exceeds the cutoff.
Timing can also affect serial interpretation. Because circulating NSE can decline relatively quickly after successful therapy, an early fall may occur before the next scheduled scan. That can be clinically encouraging, but it should not be used alone to declare complete response. Similarly, transient cell injury around treatment could change the marker without representing durable progression. Oncologists interpret the direction and persistence of the change over several measurements alongside imaging.
Monitoring and Result Meaning
NSE is most valuable when it behaves like a personal tumor marker. A high baseline that falls with treatment and rises again with active disease creates a meaningful pattern. A tumor that never raised NSE at diagnosis is unlikely to be monitored reliably with NSE alone later.
During treatment, clinicians interpret several possibilities:
- Falling NSE plus improving imaging: This pattern supports response.
- Stable NSE plus stable imaging: The disease may be stable, but the marker alone is not enough to prove it.
- Rising NSE plus worsening imaging: Progression becomes more likely.
- Rising NSE with stable imaging: Repeat the marker, assess specimen quality, and investigate other causes before assuming progression.
- Normal NSE with worsening symptoms or scans: The tumor may not be secreting NSE, so clinical progression still requires action.
There is no universal percentage change that defines response or recurrence across all NSE-secreting tumors. Disease-specific criteria and imaging remain the standard.
The baseline value matters when judging later changes. If NSE was strongly elevated before treatment and then normalized, a sustained rise back toward the pretreatment range may be more meaningful than the same absolute increase in someone whose NSE was normal from the start. Clinicians therefore compare the current result with the patient’s own history, not only with the laboratory cutoff.
Small changes near the upper reference limit deserve particular caution. Analytical variation, sample quality, and short-lived tissue injury can move a value across the “normal” line without representing a meaningful biologic change. Repeating an unexpected result under good collection conditions is often more informative than reacting to a single borderline number.
NSE also cannot determine where a tumor is located. Even when the result fits a high-grade neuroendocrine malignancy, imaging and tissue diagnosis are needed to establish the site, stage, and histologic type. The blood marker can support the overall picture, but it does not replace pathology.
If a high result is found without a known cancer, the next step depends on the clinical situation. A clinician may repeat the blood test, review for hemolysis or neurologic injury, obtain chest or abdominal imaging, or refer for specialist evaluation. NSE should guide the workup only when it fits the suspected disease.
People with a known neuroendocrine cancer should contact their treatment team about a sustained marker rise, especially if it is accompanied by new cough, shortness of breath, chest pain, unexplained weight loss, bone pain, neurologic symptoms, or other changes. The marker itself does not cause symptoms; it is a signal that must be linked to the underlying condition.
References
- NSE – Overview: Neuron-Specific Enolase, Serum 2026
- Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development-A Comprehensive Review. 2024 (Review)
- Established and novel circulating neuroendocrine tumor biomarkers for diagnostic, predictive and prognostic use 2023 (Review)
- Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future 2022 (Review)
- Improving the screening ability of neuron-specific enolase on small cell lung cancer 2025
- Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis 2020 (Systematic Review)
Disclaimer
This article provides general information about serum NSE testing and is not a diagnosis of small cell lung cancer or another neuroendocrine tumor. NSE can be affected by hemolysis, neurologic injury, assay differences, and non-neuroendocrine conditions, so results should be interpreted with imaging, pathology, and clinical findings. New or worsening cancer-related symptoms or a sustained marker rise should be discussed promptly with the treating clinician.
